Catalio Capital Management sells Recognify Life Sciences
RL-007, studied in 500 subjects, adds a second clinical-stage cognition program alongside AmyriAD’s lead asset ismidenon.
AmyriAD Therapeutics, a clinical-stage biopharmaceutical company focused on cognition in central nervous system disorders, acquired Recognify Life Sciences, a biotech developing RL-007 (inidascamine) for cognitive impairment associated with schizophrenia and Alzheimer’s disease. The all-share transaction makes former Recognify backers Catalio Capital Management, atai Life Sciences and Sudhoff Family Office shareholders in AmyriAD.
RL-007, studied in 500 subjects, adds a second clinical-stage cognition program alongside AmyriAD’s lead asset ismidenon.
Get Buyout Desk email updates.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up on the site. Email updates are not on a fixed schedule.